These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26585933)

  • 1. A Comprehensive Insight into the Chemical Space and ADME Features of Small Molecule NS5A Inhibitors.
    Ivanenkov YA; Veselov MS; Shakhbazyan AG; Aladinskiy VA; Aladinskaya AV; Yartseva SM; Majouga AG; Vantskul AS; Leonov SV; Ivachtchenko AV; Koteliansky VE
    Curr Top Med Chem; 2016; 16(12):1372-82. PubMed ID: 26585933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Silico Approaches to the Design of NS5A Inhibitors.
    Ivanenkov YA; Veselov MS; Aladinskiy VA; Shakhbazyan AG; Yartseva SM; Majouga AG; Aladinskaya AV; Vantskul AS; Leonov SV; Ivachtchenko AV; Koteliansky VE
    Curr Top Med Chem; 2016; 16(12):1383-91. PubMed ID: 26585932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015).
    Ivanenkov YA; Aladinskiy VA; Bushkov NA; Ayginin AA; Majouga AG; Ivachtchenko AV
    Expert Opin Ther Pat; 2017 Apr; 27(4):401-414. PubMed ID: 27967269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic cores.
    Henderson JA; Bilimoria D; Bubenik M; Cadilhac C; Cottrell KM; Denis F; Dietrich E; Ewing N; Falardeau G; Giroux S; L'Heureux L; Liu B; Mani N; Morris M; Nicolas O; Pereira OZ; Poisson C; Reddy TJ; Selliah S; Shawgo RS; Vaillancourt L; Wang J; Xu J; Chauret N; Berlioz-Seux F; Chan LC; Das SK; Grillot AL; Bennani YL; Maxwell JP
    Bioorg Med Chem Lett; 2015 Feb; 25(4):948-51. PubMed ID: 25577039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors.
    Ivashchenko AA; Ivanenkov YA; Aladinskiy VA; Karapetian RN; Koryakova AG; Ryakhovskiy AA; Mitkin OD; Kravchenko DV; Savchuk NP; Zagribelnyy BA; Ivashchenko AV
    Bioorg Med Chem; 2020 Oct; 28(20):115716. PubMed ID: 33069072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class.
    Nakamura H; Fujioka S; Terui T; Okuda S; Kondo K; Tamatani Y; Akagi Y; Komoda Y; Kinoshita W; Ito S; Maeda K; Ukaji Y; Inaba T
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127361. PubMed ID: 32738974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
    Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
    Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of potent macrocyclic HCV NS5A inhibitors.
    Yu W; Vibulbhan B; Rosenblum SB; Martin GS; Vellekoop AS; Holst CL; Coburn CA; Wong M; Selyutin O; Ji T; Zhong B; Hu B; Chen L; Dwyer MP; Jiang Y; Nair AG; Tong L; Zeng Q; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Fells J; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3793-9. PubMed ID: 27282743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.
    Amblard F; Zhang H; Zhou L; Shi J; Bobeck DR; Nettles JH; Chavre S; McBrayer TR; Tharnish P; Whitaker T; Coats SJ; Schinazi RF
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2031-4. PubMed ID: 23466233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
    Yu W; Coburn CA; Yang DY; Meinke PT; Wong M; Rosenblum SB; Chen KX; Njoroge GF; Chen L; Dwyer MP; Jiang Y; Nair AG; Selyutin O; Tong L; Zeng Q; Zhong B; Ji T; Hu B; Agrawal S; Xia E; Zhai Y; Liu R; Kong R; Ingravallo P; Asante-Appiah E; Nomeir A; Fells J; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3158-3162. PubMed ID: 27180013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development.
    Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer MP; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Allard ML; Buckle RN; Gauuan PJ; Holst CL; Martin GS; Naicker KP; Vellekoop S; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Mar; 26(5):1475-9. PubMed ID: 26850003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
    Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
    Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NS5A--from obscurity to new target for HCV therapy.
    Schmitz U; Tan SL
    Recent Pat Antiinfect Drug Discov; 2008 Jun; 3(2):77-92. PubMed ID: 18673121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and development of hepatitis C virus NS5A replication complex inhibitors.
    Belema M; Lopez OD; Bender JA; Romine JL; St Laurent DR; Langley DR; Lemm JA; O'Boyle DR; Sun JH; Wang C; Fridell RA; Meanwell NA
    J Med Chem; 2014 Mar; 57(5):1643-72. PubMed ID: 24621191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Non-Nucleocide NS5B Protein Inhibitors for the Treatment of Chronic Hepatitis C Infection.
    Shan LH; Liu Y; Li YH; Liu HM; Ke Y
    Curr Top Med Chem; 2016; 16(12):1392-401. PubMed ID: 26585931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile-Part 2.
    Wakenhut F; Tran TD; Pickford C; Shaw S; Westby M; Smith-Burchnell C; Watson L; Paradowski M; Milbank J; Stonehouse D; Cheung K; Wybrow R; Daverio F; Crook S; Statham K; Leese D; Stead D; Adam F; Hay D; Roberts LR; Chiva JY; Nichols C; Blakemore DC; Goetz GH; Che Y; Gardner I; Dayal S; Pike A; Webster R; Pryde DC
    ChemMedChem; 2014 Jul; 9(7):1387-96. PubMed ID: 24729518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.
    Belda O; Targett-Adams P
    Virus Res; 2012 Dec; 170(1-2):1-14. PubMed ID: 23009750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
    Yu W; Coburn CA; Nair AG; Wong M; Tong L; Dwyer MP; Hu B; Zhong B; Hao J; Yang DY; Selyutin O; Jiang Y; Rosenblum SB; Kim SH; Lavey BJ; Zhou G; Rizvi R; Shankar BB; Zeng Q; Chen L; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Nomeir A; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3800-5. PubMed ID: 27282742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.